- Home
- DHI vs EW Comparison
DHI vs EW Comparison
Compare DHI & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHI
- EW
- Stock Information
- Founded
- DHI 1978
- EW 1958
- Country
- DHI United States
- EW United States
- Employees
- DHI N/A
- EW 15800
- Industry
- DHI Homebuilding
- EW Industrial Specialties
- Sector
- DHI Consumer Discretionary
- EW Health Care
- Exchange
- DHI Nasdaq
- EW Nasdaq
- Market Cap
- DHI 44.0B
- EW 40.7B
- IPO Year
- DHI 1992
- EW 2000
- Fundamental
- Price
- DHI $121.25
- EW $71.53
- Analyst Decision
- DHI Buy
- EW Buy
- Analyst Count
- DHI 16
- EW 20
- Target Price
- DHI $170.47
- EW $78.55
- AVG Volume (30 Days)
- DHI 4.2M
- EW 4.9M
- Earning Date
- DHI 04-17-2025
- EW 04-23-2025
- Dividend Yield
- DHI 1.32%
- EW N/A
- EPS Growth
- DHI N/A
- EW 202.39
- EPS
- DHI 13.25
- EW 6.97
- Revenue
- DHI $35,315,300,000.00
- EW $5,439,500,000.00
- Revenue This Year
- DHI $0.03
- EW $10.07
- Revenue Next Year
- DHI $5.41
- EW $9.65
- P/E Ratio
- DHI $9.15
- EW $30.57
- Revenue Growth
- DHI N/A
- EW 8.57
- 52 Week Low
- DHI $110.44
- EW $58.93
- 52 Week High
- DHI $199.85
- EW $95.25
- Technical
- Relative Strength Index (RSI)
- DHI 45.63
- EW 53.92
- Support Level
- DHI $116.66
- EW $65.94
- Resistance Level
- DHI $122.96
- EW $73.26
- Average True Range (ATR)
- DHI 6.26
- EW 2.44
- MACD
- DHI -0.20
- EW 0.17
- Stochastic Oscillator
- DHI 50.35
- EW 76.37
About DHI D.R. Horton Inc.
D.R. Horton is a leading homebuilder in the United States with operations in 126 markets across 36 states. D.R. Horton mainly builds single-family detached homes (87% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.